SOLENO THERAPEUTICS INC: Acquisition Update

If you follow Soleno Therapeutics (ticker: SLNO), there is a major update. The company is no longer an independent, publicly traded business. Here is the plain-English breakdown of what happened and what it means for you.

1. What happened?

Neurocrine Biosciences officially acquired Soleno Therapeutics on May 18, 2026. Soleno is now a wholly owned subsidiary of Neurocrine. Because of this, Soleno is no longer a standalone company, and its stock (SLNO) no longer trades on the NASDAQ.

2. What does this mean for shareholders?

The deal is finished. Under the merger agreement, each share of Soleno stock you owned was canceled. In exchange, you have the right to receive $53.00 in cash per share, minus any applicable taxes. This payment happens automatically through your brokerage account. You do not need to take any action to sell your shares; the companies handle the process for you.

3. Why did this happen?

This is a standard exit for a biotech company. Soleno spent years developing DCCR, a drug candidate to treat Prader-Willi syndrome. By selling to Neurocrine, Soleno moves its main project into a larger company. This provides the resources and expertise needed to finish drug development and bring the treatment to market. It also provides shareholders with a guaranteed cash payout, removing the risks associated with future clinical trials and regulatory hurdles.

4. Who is affected?

• Investors: If you held the stock, you are entitled to $53.00 per share. You can no longer trade SLNO on the stock market.
• The Company: The leadership has changed. Soleno’s previous directors and executive officers have stepped down and were replaced by a team appointed by Neurocrine.
• Patients: For families waiting for DCCR, this move puts the drug into the hands of a larger company with the infrastructure needed to manage the complex FDA approval process and the eventual launch of the therapy.

5. What happens next?

• Delisting: The ticker symbol SLNO is now inactive. It may disappear from your trading app or show a final value reflecting the completed merger.
• Cash Settlement: Your brokerage will process your $53.00 per share payment. If you do not see the funds in your account, contact your brokerage to confirm the status of the payment.
• Operations: Neurocrine Biosciences now controls the DCCR program. Their management team oversees all clinical and regulatory activities moving forward.

6. The Bottom Line

For investors, the story of Soleno as an independent stock is over. The uncertainty of clinical trials and FDA approvals is gone, replaced by a fixed cash price of $53.00 per share. If you held the stock, your investment has been converted into a cash payment, and the company is now a private subsidiary of Neurocrine Biosciences.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and is not professional investment advice. Always do your own research.